VIR · Vir Biotechnology, Inc. · Documents
$11.78
+0.21 (+1.82%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$1.88B
Shares
169.22M
Volume · Oct 28
514.82K
Avg daily vol (3M)
1.91M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Vir Biotechnology, Inc. expanded its board from eight to nine members and appointed Suzanne Topalian, M.D. as a Class III director, effective October 27, 2026, and to its Science and Technology Committee through the 2028 annual meeting. | 2026-10-28 | 2026-10-26 | |
| 8-K | Vir Biotechnology partnered with Gilead on three PRO-XTEN® T-cell engager candidates, with $90 million upfront, up to $45 million in preclinical milestones, up to $1.74 billion in further milestones, and tiered high single-digit to low double-digit royalties. | 2026-10-14 | 2026-10-09 | |
| 8-K | Vir Biotechnology announced FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer; Astellas Pharma Inc. and Vir Biotechnology are co-developing it, with Phase 3 trials anticipated to begin in 2027. | 2026-10-08 | — | |
| 8-K | Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. His annualized base salary is $520,000, with a 45% target bonus and a $150,000 sign-on bonus. | 2026-10-01 | — | |
| 8-K | — | 2026-08-05 | — | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-07-24 | 2026-07-20 | |
| Investor Event Transcript | — | 2026-06-30 | — | |
| 8-K | — | 2026-06-10 | 2026-06-09 | |
| 8-K | — | 2026-05-28 | 2026-05-25 | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| 8-K | — | 2026-05-06 | — | |
| DEFA14A | — | 2026-04-16 | — | |
| ARS | — | 2026-04-16 | 2025-12-31 | |
| DEF 14A | — | 2026-04-16 | 2025-12-31 | |
| 8-K | — | 2026-04-10 | 2026-04-07 | |
| Investor Event Transcript | — | 2026-03-31 | — | |
| 8-K | — | 2026-03-04 | — | |
| 8-K | — | 2026-03-02 | 2026-02-26 | |
| 8-K | — | 2026-02-26 | 2026-02-25 | |
| 10-K | — | 2026-02-23 | 2025-12-31 | |
| 8-K | — | 2026-02-23 | 2026-02-19 | |
| 8-K | — | 2026-01-12 | — | |
| Investor Event Transcript | — | 2025-12-31 | — | |
| 8-K | — | 2025-12-16 | — | |
| 8-K | — | 2025-11-05 | — | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 10-Q | — | 2025-08-06 | 2025-06-30 | |
| 8-K | — | 2025-08-06 | — | |
| 8-K | — | 2025-07-24 | — | |
| 8-K | — | 2025-05-29 | — | |
| 8-K | — | 2025-05-09 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| 8-K | — | 2025-05-07 | — | |
| DEFA14A | — | 2025-04-17 | — | |
| ARS | — | 2025-04-17 | 2024-12-31 | |
| DEF 14A | — | 2025-04-17 | 2025-05-29 | |
| 10-K | — | 2025-02-27 | 2024-12-31 | |
| 8-K | — | 2025-02-26 | — | |
| 8-K | — | 2025-01-30 | 2025-01-24 | |
| 8-K | — | 2025-01-08 | — | |
| 10-Q | — | 2024-11-04 | 2024-09-30 | |
| 8-K | — | 2024-10-31 | — | |
| 8-K | — | 2024-09-10 | 2024-09-06 | |
| 8-K | — | 2024-08-01 | 2024-07-29 | |
| 10-Q | — | 2024-08-01 | 2024-06-30 | |
| 8-K | — | 2024-08-01 | 2024-07-31 | |
| 8-K | — | 2024-06-26 | — | |
| 8-K | — | 2024-06-05 | — | |
| 8-K | — | 2024-05-29 | — |
Showing 1–50 of 157 filings
Key facts
CIK
1706431
CUSIP
92764N102
13F (30d)
43 filings
43 filers
Visit website
Investor relations